ADMA Biologics, Inc.
(NASDAQ : ADMA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.63%105.161.1%$1250.41m
GILDGilead Sciences, Inc.
0.43%72.820.9%$635.59m
AMGNAmgen Inc.
0.07%169.961.1%$483.52m
BIIBBiogen Inc.
0.24%309.801.2%$426.39m
REGNRegeneron Pharmaceuticals, Inc.
0.81%387.542.7%$354.48m
ALXNAlexion Pharmaceuticals, Inc.
-0.42%107.601.9%$279.93m
VRTXVertex Pharmaceuticals Incorporated
1.33%147.041.9%$234.21m
ALNYAlnylam Pharmaceuticals, Inc
0.24%132.3310.0%$190.13m
INCYIncyte Corporation
0.05%99.002.5%$178.71m
NKTRNektar Therapeutics
-0.46%49.756.1%$170.43m
ILMNIllumina, Inc.
1.56%215.353.5%$165.34m
JUNOJuno Therapeutics, Inc.
2.65%60.3313.5%$136.10m
AAgilent Technologies, Inc.
-1.75%68.691.5%$131.83m
SRPTSarepta Therapeutics, Inc.
0.66%56.2216.8%$117.39m
BLUEBluebird Bio, Inc.
-0.03%167.2017.2%$114.30m

Company Profile

ADMA Biologics, Inc. is a biopharmaceutical company, which develops, manufactures and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the Plasma Collection Center and Research and Development segments. The Plasma Collection Center segment comprises of operations in Georgia. The Research and Development segment involves plasma development operations in New Jersey. The company's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA Biologics was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.